MicroIslet Inc. and Progenitor Cell Therapy Enter Into Agreement for the Manufacturing of MicroIslet-P, an Encapsulated Islet Cell Product for the Treatment of Type 1 Diabetes

SAN DIEGO and HACKENSACK, N.J., Sept. 17, 2007 (PRIME NEWSWIRE) -- MicroIslet, Inc. (OTCBB:MIIS), a development-stage biotechnology company with patented and proprietary technologies focused on transplantation therapy for people with insulin-dependent diabetes, and Progenitor Cell Therapy, LLC (PCT), a leading cell therapy services company, announced today that they have signed an agreement for the manufacturing of MicroIslet's premier product, MicroIslet-P(tm).